AI assistant
CONTROL BIONICS LIMITED — Capital/Financing Update 2024
Dec 19, 2024
64611_rns_2024-12-19_16da7573-8568-4022-9d3a-706a85c1f449.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [177 x 63] intentionally omitted <==
20 December 2024
CONTROL BIONICS ISSUES SHORTFALL SHARES
Control Bionics Limited ( CBL ) is pleased to announce that it has raised a total of $310,000 from the issue of shortfall shares from its recently completed Non-Renounceable Rights Issue.
This has resulted in the issue of approximately 4.428 million shares at an issue price of 7c per share and 2.214 million options exercisable at 10c per option with an expiry date of 10 October 2026.
The placement of the shortfall shares was arranged by Lynx Advisors Pty Ltd. Lynx will be issued with 650,000 options in consideration for the arranging the placement.
This announcement is authorised by CBL’s CEO – Jeremy Steele.
For further information, please contact:
Investors and Media
Jeremy Steele – CEO and Managing Director [email protected]
Brett Crowley - Company Secretary [email protected]
Investor Relations:
Joe Durak Executive Director & Founder Lynx Advisors [email protected] +61 414 465 582
Control Bionics Limited Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria 3121, Australia T: +61 3 9897 3576
W: www.controlbionics.com ABN: 45 115 465 462
For further information visit the website: https://www.controlbionics.com/
About Control Bionics:
Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like
Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462
==> picture [177 x 63] intentionally omitted <==
email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.
Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time. DROVE recently got approved by the TGA as a Class I medical device.
Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip ® . This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.
Control Bionics operates in North America, Australia, Singapore and Japan.
About Control Bionics:
Control Bionics Limited Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462